ArticleFrontiers in immunology2026
Construction of circadian clock signature for tumor microenvironment in predicting survival of esophageal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a distinct subtype of esophageal cancer (EC). Research indicates that circadian clock genes (CCGs) in human ESCC are dysregulated. However, the significance of CCGs in ESCC prognosis remains ambiguous. This study sought to establish a complete signature of ESCC-specific differentially expressed CCGs (DE-CCGs) associated with prognosis, tumor growth, and immunological infiltration. Methods: Differentially expressed genes (DEGs) between normal and ESCC samples in TCGA database and the GSE23400 dataset were intersected with CCGs to obtain DE-CCGs. The prognosis-related DE-CCGs were discerned to develop a risk model using univariate Cox regression and LASSO regression analyses in TCGA-ESCC. The accuracy of the model was validated using risk and overall survival profiles. Results: Seven DE-CCGs (CST3, C1QBP, TTF2, EGFR, CDKN2A, PFAS, TRRAP) were identified in TCGA-ESCC, which were correlated with unfavorable ESCC prognosis. The immune infiltration analysis revealed that High-risk ESCC patients displayed enhanced tumor infiltration. And the combination of CST3 and PD-L1 expression may serve as a potential marker for predicting prognosis of ESCC patients. Moreover, in Vitro experimental models, CST3 expression was markedly elevated in tumor cells and associated with ESCC growth. Conclusions: This research illustrated the prognostic significance of seven DE-CCGs for ESCC patients based on tumor progression and immune infiltration. And the CST3 may serve as an independent prognostic biomarker and a potential therapeutic target for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.